AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

RecruitingPhase 2Ages 18 Years - 75 YearsAllSecond Affiliated Hospital, Zhejiang University, โ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age โ‰ฅ18 years old and โ‰ค75 years old. * Pathologically diagnosed MSS or pMMR-type colon adenocarcinoma. * The lower edge of the tumor is more than 12cm from the anus as measured by colonoscopy and the lower edge of the tumor cannot be directly palpated during rectal examination. * Enhanced CT stage T3/4 or T1-4N+ without multiple primary tumors or distant metastasis. * Life expectancy is expected to be more than 1 year. * First diagnosis, no previous anti-tumor treatment received, and no chemotherapy contraindications. * Informed consent, able to understand the study protocol and willing to participate in the study, and will provide written informed consent. Exclusion Criteria: * Refused to participate in this study. * Multifocal colorectal cancer. * History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers. * Cannot tolerate chemotherapy, such as but not limited to bone marrow suppression. * Acute exacerbation of important organ diseases (such as but not limited to COPD, coronary heart disease, and renal insufficiency) and/or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia, and myocarditis), ASA score \> 3 points. * Mental disorders, illiteracy, or language communication barriers that prevent the understanding of the study protocol. * Tumor obstruction or high risk of obstruction, bleeding, and/or perforation. * Peripheral sensory neuropathy, unable to receive oxaliplatin-based chemotherapy. * Pregnancy or lactation. * Unable to undergo enhanced CT examination or having comorbidities requiring the use of glucocorticoid therapy. * Continuous use of glucocorticoids for more than 3 days within 1 month prior to signing the informed consent form. * CT or MRI in the mid-sagittal plane shows that the lower border of the tumor is below the line connecting the sacrococcygeal promontory and the upper border of the pubic symphysis. * Other situations in which the researcher deems unsuitable for this study.
๐Ÿ’Š

What it tests

  • Oxaliplatin
  • Capecitabine
  • Anti-PD-L1 Monoclonal Antibody
  • Clostridium butyricum
  • Colectomy
๐Ÿ“

Where

1 site
Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy